Shinichiro Komoto

Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023.

Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023.

Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023.

Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023.

Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023.